Dr. Rachel Tate uptoTate
3 years 6 months ago
2022 EULAR recs for RA treatment @RheumNow @RWCSmtg #RWCS23 https://t.co/nWCcFJyIhz
Dr. John Cush RheumNow
3 years 6 months ago
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live!
Among our 24 speakers, Dr. Sergio and Monica Schwartzman will cover All in the Family Rheumatology. Dr. Philip Conaghan will cover Insights into the Future of OA and more.
https://t.co/gAKQYxhTMY https://t.co/zMOGfhRrg2
Dr. John Cush RheumNow
3 years 6 months ago
Know Your Numbers! Have a chance to tune in to last week's podcast?
https://t.co/A6bYIahvBF https://t.co/ZAgZ3FvL0H
Dr. John Cush RheumNow
3 years 6 months ago
Lg vessel US study compared 44 LV-GCA vs 42high-risk atherosclerosis pt.Intima-media thickness (IMT) was signif. higher w/ GCA. IMT ≥ 1 mmseen in 31/44 axillary, 30/44 subclavian in GCA; but only in 2/42 axillary & 3//42 subclavian in atherosclerosis grp.https://t.co/DGMOfflcVR https://t.co/QVBbdrcd3I
Dr. John Cush RheumNow
3 years 6 months ago
Retrospective study of 64 gout pts having orthopedic surgery - perioperative flares more likely with Incr SUA, DM, tophi and diuretics. In 12 mos following surgery, recurrent gout more if ^SUA (45% vs 11%) & those w/ topic ((RR = 4.8; P = 0.029) https://t.co/iMDSWnb5Dv https://t.co/ZwUKBkZbSL
Dr. John Cush RheumNow
3 years 6 months ago
NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
Dr. John Cush RheumNow
3 years 6 months ago
Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky
Dr. John Cush RheumNow
3 years 6 months ago
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/
b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−)
RTX 9% (p .03)
ABA 6%
JAKi 1%
IL‐6i 0%
TNFi 0%
Safe to use TNFi, JAKi, IL6 mAbs
https://t.co/YCIISZTigX https://t.co/RmzAObr6w1
Dr. John Cush RheumNow
3 years 6 months ago
Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts.
https://t.co/tsKuLZw7dQ
Dr. John Cush RheumNow
3 years 6 months ago
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/hQOwBQtOny https://t.co/wwNF0gjpEj
Dr. John Cush RheumNow
3 years 6 months ago
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of DMARDs, according to Seminars in Arthroplasty.
https://t.co/iGAQaa7Ppc https://t.co/AbteC427wI
Dr. John Cush RheumNow
3 years 6 months ago
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/tNNpFC6LiN https://t.co/x8Fuus2r8O
Dr. John Cush RheumNow
3 years 6 months ago
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep
Dr. John Cush RheumNow
3 years 6 months ago
Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral). https://t.co/ZbXuPAJcGv https://t.co/pai4gmMKoI
